KAUST Professor Pierre Magistretti participated in the U.S.-Saudi Arabia Business Leaders Virtual Forum, organized by the U.S. Chamber of Commerce and the Saudi Ministry of Investment. Magistretti spoke on a panel about healthcare innovation alongside representatives from Pfizer, Abbott, and the Saudi Ministry of Investment. KAUST's Smart-Health Initiative (SHI) aims to translate scientific discoveries into clinical tools. Why it matters: This participation highlights KAUST's growing role in shaping healthcare innovation within the Kingdom and fostering international collaborations in the field.
SaudiVax, located in the KAUST Research & Technology Park, is collaborating with the University of Pittsburgh and Merck France to develop a COVID-19 antibody injection. The antibody both protects against potential infection and neutralizes the virus in those already infected. SaudiVax is utilizing KAUST expertise and has contracted with Merck France for manufacturing since suitable facilities are not yet available in Saudi Arabia. Why it matters: This partnership highlights the growing biopharmaceutical capabilities in Saudi Arabia and the potential for KAUST to serve as a hub for medical innovation in the region.
The KAUST Smart-Health Initiative (KSHI) held its annual forum, showcasing research collaborations with partners like KFSHRC, KAIMRC, and KACST. Projects presented included biomarker detection devices, cardiovascular disease sensors, 3D data visualization, and genome sequencing for patient data analysis. Dr. Sara F. Althari highlighted KAUST's cultivation of partnerships within the Kingdom's healthcare and biotech ecosystem. Why it matters: The KSHI aims to transform Saudi Arabia's healthcare system towards precision and personalized medicine, aligning with Vision 2030.
Freddy Jimenez, regional innovation lead for Pfizer in the Middle East, Africa, and Russia, is working to implement AI solutions for healthcare challenges in the UAE. Jimenez joined the Executive Education Program at MBZUAI to expand his knowledge and drive the country's healthcare industry forward. He emphasizes the importance of strategic approaches to AI in healthcare due to rapid technological advancements outpacing regulation. Why it matters: This highlights the UAE's focus on leveraging AI to improve healthcare outcomes and the importance of collaboration between industry, academia, and government to accelerate AI adoption in the heavily regulated healthcare sector.
KAUST highlights postdoctoral fellows Yi Jin Liew, Isabelle Schulz, Maren Ziegler and Neus Garcias Bonet outside the University Library. The article mentions King Abdullah bin Abdulaziz Al Saud (1924 – 2015). It encourages applications to KAUST's Discovery Postdoctoral program. Why it matters: This brief announcement signals KAUST's ongoing investment in attracting international research talent to Saudi Arabia.
Michael Hickner, an Associate Professor from Penn State University, visited KAUST as part of the CRDF-KAUST-OSR Visiting Scholar Fellowship Program. Hickner specializes in Materials Science and Engineering, Chemistry, and Chemical Engineering. The visit was documented with photos by Meres J. Weche. Why it matters: Such programs foster international collaboration and knowledge exchange in science and engineering between KAUST and other leading institutions.
In a 2018 keynote, Saudi Aramco VP Nasser Al-Nafisee recounted the rapid construction of KAUST. Al-Nafisee described building KAUST in under three years as a "mission impossible" requiring immense effort. He advised KAUST attendees to push beyond their comfort zones and adopt a "can-do attitude". Why it matters: The talk highlights the ambitious vision and rapid development that characterize Saudi Arabia's investments in research and technology.
The Research Products Development Company (RPDC) signed an agreement with The Saudi Vaccine and Biomanufacturing Center (SVBC) to establish a research and industrial center in Saudi Arabia for vaccine and biopharmaceutical development. Supported by KACST and hosted by KAUST, the SVBC will provide a state-of-the-art facility and a training platform. Cooperation agreements were also signed with GE for equipment supply and with Fujifilm Dayosent Biotechnology for MERS-CoV treatment development. Why it matters: This initiative aims to localize vaccine and advanced treatment industries in Saudi Arabia, create technical jobs, and reduce reliance on imports in line with Vision 2030.